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Background: Atopics have a lower risk for malignancies, and IgE targeted to tumors is superior to IgG in fighting
cancer. Whether IgE-mediated innate or adaptive immune surveillance can confer protection against tumors re-
mains unclear.
Objective: We aimed to investigate the effects of active and passive immunotherapy to the tumor-associated an-
tigen HER-2 in three murine models differing in Epsilon-B-cell-receptor expression affecting the levels of
expressed IgE.
Methods: We compared the levels of several serum specific anti-HER-2 antibodies (IgE, IgG1, IgG2a, IgG2b, IgA)
and the survival rates in low-IgE ΔM1M2 mice lacking the transmembrane/cytoplasmic domain of Epsilon-B-cell-
receptors expressing reduced IgE levels, high-IgE KN1 mice expressing chimeric Epsilon-Gamma1-B-cell receptors
with 4-6-fold elevated serum IgE levels, and wild type (WT) BALB/c. Prior engrafting mice with D2F2/E2
mammary tumors overexpressing HER-2, mice were vaccinated with HER-2 or vehicle control PBS using the Th2-
adjuvant Al(OH)3 (active immunotherapy), or treated with the murine anti-HER-2 IgG1 antibody 4D5 (passive
immunotherapy).
Results: Overall, among the three strains of mice, HER-2 vaccination induced significantly higher levels of HER-2
specific IgE and IgG1 in high-IgE KN1, while low-IgE ΔM1M2 mice had higher IgG2a levels. HER-2 vaccination
and passive immunotherapy prolonged the survival in tumor-grafted WT and low-IgE ΔM1M2 strains compared
with treatment controls; active vaccination provided the highest benefit. Notably, untreated high-IgE KN1 mice
displayed the longest survival of all strains, which could not be further extended by active or passive
immunotherapy.
Conclusion: Active and passive immunotherapies prolong survival in wild type and low-IgE ΔM1M2 mice
engrafted with mammary tumors. High-IgE KN1 mice have an innate survival benefit following tumor challenge.Background
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J. Singer et al. World Allergy Organization Journal 12 (2019) 1000442, HER-2.1 This humanized IgG1 antibody leads to improved overall
response rates and better progression-free as well as overall survival.2
Trastuzumab is a derivative of the mouse monoclonal antibody 4D5,
an IgG1 antibody clone targeting human HER-2.3 Because of its favorable
binding affinity and tumor growth inhibition, the
complementarity-determining regions of 4D5 were inserted into the
backbone of a human IgG1 antibody with increased affinity to HER-2 as a
positive side-effect.4 All antibodies currently FDA-approved are of the
IgG isotype,5 although nature has equipped the human immune system
with five different immunoglobulin classes.6
IgE antibodies have gained attention in the past for their potential
protective role in cancer.7,8 IgE antibodies purified from pancreatic
cancer patients were capable of mediating antibody-dependent cell-me-
diated cytotoxicity (ADCC) against pancreatic cancer cells in vitro.9 In
vitro, higher levels of ADCC could be triggered by IgE antibodies,
compared to their IgG counterparts.10,11 This points towards a superior
function of IgE in ADCC, compared to IgG, which is known to likely
induce antibody-dependent cellular phagocytosis (ADCP).12–19 Large
epidemiological studies demonstrated inverse correlations between
elevated IgE levels in atopics and malignant diseases, including colo-
rectal, pancreatic, and gynecological cancers as well as gliomas, and
childhood leukemia.16,20–30 Moreover, recent epidemiological studies
displayed an association of very low IgE levels (termed “IgE-deficient”)
with higher rates of malignancies,31 independently of other risk factors,
such as concomitant common variable immunodeficiency.32
IgE could thus play a considerable role in natural tumor immune
surveillance, and potentially can be exploited in anticancer immuno-
therapy according to numerous studies, which support the AllergoOn-
cology concept.7,8,33–38
However, it remains unclear whether serum IgE levels and IgE-
mediated innate or adaptive immune surveillance can confer protection
against tumors,33 or vice versa, low IgE levels are in favor of tumor
development.31,32 Therefore, we investigated the impact of IgE against
cancer at low-, normal- or high-IgE conditions in a mouse model. In order
to address these aspects, we compared the levels of specific IgE and
several other serum specific anti-HER-2 antibodies (IgG1, IgG2a, IgG2b,
IgA) along with the survival rates between three different mouse strains
engrafted with HER-2 overexpressing tumors, differing in their
Epsilon-B-cell receptor expression and IgE expression levels: i) low-IgE
ΔM1M2 mice lacking the transmembrane/cytoplasmic domain of the
ε-B-cell receptor (BCR),39 ii) high-IgE KN1 mice expressing chimeric
ε-γ1-BCRs with a 4 -to 6- fold elevated mean serum IgE level,40 compared
to iii) wild type (WT) BALB/c mice with “normal” IgE levels.
Materials and methods
Cell lines, recombinant proteins and monoclonal antibodies
D2F2/E2 is a mouse mammary carcinoma cell line derived from D2F2
cells transfected with human HER-2. This cell line was established41 and
kindly provided by Prof. Wei-Zen Wei (Karmanos Cancer Institute,
Wayne State University School of Medicine, Detroit, Michigan, USA).
D2F2/E2 cells were grown in a humidified atmosphere of 5% CO2 at 37
C in IMDM medium supplemented with 10% fetal calf serum (FCS),
penicillin (100 U/mL), streptomycin (100 μg/mL) and 1 mg/ml geneticin
(G418). Recombinant human HER-2 (rHER-2) was produced as previ-
ously described42,43 in Lec-1 cells (a kind gift of Prof. Daniel J. Leahy, The
Johns Hopkins University School of Medicine, Baltimore, Maryland,
USA). Lec-1 cells were kept in DMEM/F12, supplemented with 5% FCS,
100 nM methotrexate and 10 μg/mL gentamicin sulfate. Trastuzumab
(Herceptin®), a humanized IgG1 monoclonal anti-ErbB-2 (HER-2) anti-
body, was obtained from Roche (Basel, Switzerland). Rituximab (Mab-
Thera®), a chimeric IgG1 anti-CD20monoclonal antibody, was employed
as isotype control in ELISAs. Clone 4D5, the murine IgG1 precursor of
trastuzumab was kindly provided by Genentech (South San Francisco,
California, USA).2Mouse strains
Mice with different degrees of IgE-responses to foreign antigens were
employed in this study. BALB/c mice served as wild type animals (WT).
ΔM1M2mice, which lack the transmembrane and cytoplasmic domain of
IgE39 served as the IgE-reduced (IgE low) strain. KN1mice, which express
chimeric ε-γ1 B-cell receptors40 served as the IgE-overexpressing
(high-IgE) model. Both transgenic mouse strains are of BALB/c
background.
All mice were kept on the basis of authorization of the Animal Ethics
Committee of theMedical University according to the Austrian, European
Union and Federation for Laboratory Animal Science Associations
(FELASA) guidelines for animal care and protection (GZ: BMWF-66.009/
0086-C/GT/2007).
Immunization scheme and tumor graft trial
In order to achieve specific immunity to HER-2, mice were vaccinated
subcutaneously four times at 2-week intervals with 50 μg of rHER-2
adjuvanted with aluminum hydroxide solution (Al(OH)3, Alum, Alu-
Gel-S®, Cat-No.: 12261.01,Serva, Heidelberg, Germany). Control groups
received phosphate buffered saline (PBS). Before the immunization trial
and after each round of immunization serum samples were taken to
monitor the immune response (Fig. 1, PIS… Pre-Immune Serum,MIS 1–4
… Mouse Immune Serum 1–4). For overview on mouse groups, strains
and treatments see Table 1.
On day 1 of tumor challenge experiments, immunized mice were
grafted subcutaneously into their left flanks with 2  106 HER-2 over-
expressing D2F2/E2 mouse mammary carcinoma cells, resuspended in
100 μl of IMDM (without supplements). Tumor size was measured daily
by caliper measurement and tumor volume was calculated according to
formula V (mm3)¼ d2 (mm2) x D (mm)/2, where d stands for the smallest
and D for the largest diameter of the tumor. When tumors reached a
volume of 300 mm3, mice had to be sacrificed and tumors were taken for
histologic evaluation of HER-2 expression.
In order to treat one group with passive anti-HER-2 immunotherapy,
respective mice received 100 μg 4D5 antibody intraperitoneally (i.p.) 1
day before the tumor graft and every 7 days after tumor transplantation.
MIS5 (Mouse Immune Serum) was taken at day 14 of the tumor trial.
Mice were sacrificed when tumor volume reached 300 mm3 MIS6 was
taken prior to sacrifice (at individual time points; see Fig. 1).
Enzyme linked immunosorbent assay (ELISA)
Immune responses in mice were evaluated by ELISA. The tumor-
associated antigen rHER-2 was coated on 96-well microtiter plates
(Immuno Maxi-Sorp™, Nunc, Cat-No: M9410-1CS, Roskild, Denmark) at
a concentration of 1 μg/ml. Unspecific binding was blocked with 1%
dried milk powder (DMP) in TRIS-buffered saline, 0.05% Tween20
(TBST). Sera of treated mice, diluted in TBST/0.1% DMP, were allowed
to adhere overnight on 4 C. Bound murine immunoglobulins were
detected with rat anti-mouse IgM (Cat-No: 553405), IgG1 (Cat-No:
553440), IgG2a (Cat-No: 553387), IgG2b (Cat-No: 553392), IgA (Cat-No:
556960) and IgE (Cat-No: 553416) antibodies (Pharmingen™, BD Bio-
sciences, Franklin Lakes, New Jersey, USA), followed by detection of
bound antibodies with a horseradish-peroxidase labeled goat anti-rat IgG
antibody (Amersham ECL, GE Healthcare Europe GmbH; Cat-No: NA935;
diluted 1:3000 in TBST þ 0.1% DMP, Buckinghamshire, United
Kingdom). For detection, 3,30,5,50-tetramethylbenzidine (TMB, BD
OptEIA TMB Solution, BD Biosciences; Cat-No: 555214; 100μl/well) was
added and the optical density (OD) was measured at 450 nmwith 620 nm
as reference wavelength with a multiwell plate reader (Infinite M200
PRO, Tecan Group AG, Maennedorf, Switzerland). For standard dilution
curves, the following purified mouse immunoglobulins from Southern
Biotechnologies were used: mouse IgM clone 11E10 (Cat-No.: 0101-01),
mouse IgG1 clone 15H6 (Cat-No.: 0102-01), mouse IgG2a clone HOPC
Fig. 1. Schematic overview of immunization plan
and tumor graft trial. Mice were immunized 4 times
with rHER-2 or PBS þ Al(OH)3 in bi-weekly intervals
(top panel, bottom panel). Mouse sera were taken to
monitor the immune response (PIS ¼ Pre-
ImmuneSerum, MIS 1-4 ¼ Mouse Immune Serum).
Subsequently mice were grafted 2x106 HER-2 over-
expressing D2F2/E2 cells s.c.; tumor growth was
measured daily by caliper measurement. Passive
immunotherapy groups received the murine anti-HER-
2 antibody 4D5 i.p. 1 day prior to tumor grafting and
every 7 days after tumor transplantation (middle
panel). MIS5 was taken at day 14 of the tumor trial.
Mice were sacrificed when tumor volume reached
300mm3. MIS6 was taken prior to sacrifice (at indi-
vidual time points).
J. Singer et al. World Allergy Organization Journal 12 (2019) 100044
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KN1 (high IgE levels) rHER-2 4D5 PBS
J. Singer et al. World Allergy Organization Journal 12 (2019) 100044(Cat-No.: 0103-01), mouse IgG2b clone A-1 (Cat-No.: 0104-01), mouse
IgA clone S107 (Cat-No.: 0106-01) and mouse IgE clone 15.3 (Cat-No.:
0114-01).Data handling and statistics
Sera of animals were tested in duplicates for the presence of HER-2
specific antibodies. Levels at MIS4 and MIS6 were analyzed by means
of one way-ANOVA followed by Tukey's multiple comparison's test.
Statistical analysis of survival experiments was performed by plotting
Kaplan-Meier curves of animal groups were and analyzed applying Log-
rank (Mantel-Cox) Test.
In all statistical calculations of this study, significance was accepted at
p < 0.05 (*), p < 0.01 (**), p < 0.001 (***) and p < 0.0001 (****).
Statistical analyses were performed with GraphPad Prism (Version 7.0b).
Results
High-IgE expressing mice respond to HER-2 immunization by
enhancing anti- HER-2 IgE and IgG1, while low-IgE ΔM1M2 mice
develop higher IgG2a levels.
In mice of all three strains immunoglobulins could be specifically
induced by the HER-2 vaccine (Fig. 2). IgG1was by far themost prominent
immunoglobulin isotype response in all three strains (Fig. 2A). After 4
immunizations (MIS4, Fig. 3),WTBALB/cmice displayed significantly less
HER-2 specific IgG1 than high-IgE expressing KN1 (p < 0.0001, Fig. 3A),
andmore than low-IgE expressingΔM1M2 (n.s., p¼ 0.346)mice.ΔM1M2
mice developed significantly higher levels of anti-HER-2 IgG2a (Fig. 2B)
than eitherWTBALB/c (p< 0.0001, Fig. 3B) or KN1 (p< 0.0001, Fig. 3B).
Both WT BALB/c and KN1 mice (Fig. 2C) displayed comparable (p ¼
0.5633), but significantly higher IgG2b levels than ΔM1M2 mice (p <
0.0001 for WT BALB/c; p ¼ 0.0023 for KN1; Fig. 3C). For HER-2 specific
IgA, the serum levels did not significantly differ between the three stains
(WT BALB/c: ΔM1M2: p¼ 0.388; WT vs KN1: p¼ 0.9819; KN1: ΔM1M2:
p ¼ 0.2725; Figs. 2D and 3D). Notably, after 4 rounds of immunization,
HER-2 specific IgE levelswere highest in the KN1 animals (p< 0.0001) but
did not differ between normal-IgEWT BALB/c vs low-IgEΔM1M2mice (p
¼ 0.8993; Figs. 2E and 3E). The induction of HER-2 specific IgE occurred
more slowly in ΔM1M2 mice (Fig. 2E).
Together, these findings suggest that high-IgE expressing mice
develop a prominent IgE-enhanced response following HER-2
vaccination.Active and passive immunotherapy do not further prolong the survival rates
in high-IgE mice
Following tumor challenge, WT HER-2-vaccinated mice had a sig-
nificant survival benefit over PBS-treated control mice (Fig. 4A, left p <
0.0001), which exceeded the effect of passive immunotherapy with the
HER-2 specific monoclonal IgG1 antibody 4D5 (Fig. 4A, middle, p ¼
0.0428). 4D5 treatment, however, provided a significant survival benefit
compared to PBS sham treatments. (Fig. 4A, right, p ¼ 0.0013).
In low-IgE ΔM1M2mice, the HER-2 vaccine (p ¼ 0.0001) and 4D5 (p
¼ 0.0081) prolonged survival compared to PBS (Fig. 4B left and middle).
Again, survival of the HER-2 vaccinated mice was more pronounced than4in mice treated with 4D5 (Fig. 4B right: HER-2 vs. 4D5 treated, p ¼
0.0251).
In the high-IgE KN1 group, neither HER-2 immunization (Fig. 4C left,
p¼ 0.1557) nor 4D5mediated any additional survival benefits compared
to naïve animals (Fig. 4C middle, p ¼ 0.8475).
Notably, untreated high-IgE KN1 mice displayed significantly longer
survival after tumor grafting than both WT and ΔM1M2 mice (Fig. 5A,
middle and right).
Discussion
Promising approaches employ alternate immunoglobulin classes,
such as IgA or IgE, to the commonly used IgG for cancer immuno-
therapy.10,19,44–46 A trastuzumab-like IgE with the same variable region
and differing only in the constant region, mediated higher levels of ADCC
in a side-by-side comparison with the corresponding IgG1 in vitro.10
These functional studies in parallel with data from epidemiological
meta-analyses describing a negative correlation of specific and total IgE
levels in allergics and atopics with the occurrence of specific cancers
suggest that elevated levels of IgE antibody responses such as in allergy
and atopy, may offer protection from cancer initiation.23–32 In accor-
dance with these observations, recent retrospective studies demonstrate
that vice versa low levels of total IgE in 4488 patients of the 2005–2006
US National Health and Nutrition Examination Survey (NHANES) termed
“IgE-deficient”, correlated with a higher frequency of occurrence of
cancer, compared with normal, high, or very high IgE levels.31 In another
study, the authors showed that in fact 2.7% of 2339 allergics visiting an
outpatient allergy clinic correlated with significantly higher rates of
diagnosis of any type of cancer during the observation period of
2010–2015 (33% vs 8.7%; odds ratio 5.51, 95% confidence interval
3.07e9.88).32
In the present study, we mimic the human setting of high, atopic IgE
levels, versus low IgE levels employing three different mouse strains
differing in their ε-B-cell receptor expression. Our findings confirm that
IgE antibodies have a protective effect, in a model of HER-2 positive
mammary cancer, even in a non-antigen specific manner.
In high-IgE KN1mice, higher expression of the ε-BCR and of IgE seem
to play a decisive role in significantly enhancing tumor-free survival
time independent of active or passive immunotherapy. In WT and low-
IgE ΔM1M2 mice, both passive and active immunotherapy signifi-
cantly prolonged mouse survival, compared to sham treatments. These
findings suggest the merit of anticancer immunotherapies targeting the
tumor-associated antigen HER-2. Notably, high-IgE mice survived
significantly longer than normal- and low-IgE mice following mammary
tumor challenge when no immunotherapy was made. In the high-IgE
KN1 mice, mimicking the atopic state in humans (Fig. 5A), the
“innate” effects of high IgE could not be further increased by specific
anti-HER-2 vaccination, or by passive anti-HER-2 IgG1 antibody treat-
ment using 4D5. This is in favor of previous work demonstrating an
innate “adjuvant function” of IgE in cooperation with FcεRI expressed by
cytotoxic effector cells.38 In concordance, a gene expression signature
incorporating the high affinity IgE receptor FcεRI was shown to corre-
late with improved prognosis in lung adenocarcinoma.47 These findings
mirrored numerous epidemiologic studies highlighting an inverse cor-
relation of high total or allergen-specific IgE in atopic and allergic pa-
tients, with the reduced risk of developing different cancers including
those of the breast.
When mice were treated with passive or active immunotherapy, the
advantage of innate IgE in KN1 was lost and all strains had a similar
survival benefit (Fig. 5B and C). Based on these data we propose that low-
IgE patients might have the greatest advantage of immunotherapies,
while atopic patients already naturally exploit innate IgE-mediated
mechanisms against malignancies.
Our study has several limitations: first of all, the sample size for each
group is small, however, this is an exploratory pilot study addressing a
novel aspect in cancer immunology, which may represent the basis for
Fig. 2. Antibody responses of different mouse strains. A: HER-2 specific IgG1 antibody levels are displayed during the course of the immunization trial. Rectangle
symbols depict the groups immunized with rHER-2, triangle symbols represent the groups receiving PBS. Serum was taken prior to immunization (PIS) and after each
immunization round (MIS 1–4). Left panel depicts WT mice, middle panel ΔM1M2 mice and right panel KN1. Displayed are mean immunoglobulin levels in ng/ml 
SEM. B: HER-2 specific IgG2a antibody levels. C: HER-2 specific IgG2b. D: HER-2 specific IgA. E: HER-2 specific IgE.
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Fig. 3. Comparison of antibody responses in different mouse strains after 4 rounds of immunizations. A: HER-2 specific IgG1 levels in WT, ΔM1M2 and KN1
mice. B: HER-2 specific IgG2a antibody levels. C: HER-2 specific IgG2b. D: HER-2 specific IgA. E: HER-2 specific IgE. Displayed are mean values in ng/ml  SEM. ns…
not significant, * … p < 0.05, ** … p < 0.01, *** … p < 0.001, **** … p < 0.0001.
Fig. 4. Survival curves of different treatment groups after tumor challenge. A: Survival curves of wild type animals distributed by different treatment groups.
Left panel: HER-2 immunized animals compared to naive (PBS treated) mice, middle: mice treated with the anti-HER-2 antibody 4D5 compared to naive mice, right:
comparison of the active (HER-2 immunized) and passive (4D5 treated) immunotherapy groups. B: Survival curves of different treatment groups in the ΔM1M2
mouse strain. Left panel: HER-2 treated mice compared to naive, middle: 4D5 treated animals compared to naive, right: HER-2 immunized mice compared to 4D5
treated. C: Survival curves of differently treated mice in the KN1 strain. Left: HER-2 treatment vs. naive, middle: 4D5 treatment vs. naive, right: HER-2 immunization
vs. 4D5. Full lines: naive groups, dashed lines: HER-2 immunized groups, dotted lines: 4D5 treated groups; ns… not significant, *… p < 0.05, **… p < 0.01, ***… p
< 0.001, **** … p < 0.0001.
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Fig. 5. Survival curves of different mouse strains after tumor challenge. A: Survival curves of naive (PBS treated) animals distributed by different mouse strains.
Left panel: wild type (WT) animals compared to ΔM1M2 mice, middle: WT animals compared to mice of the KN1 strain, right: comparison of ΔM1M2 and KN1 strains.
B: Survival curves of HER-2 immunized animals distributed by different mouse strains. Left panel: WT mice compared to ΔM1M2, middle: WT animals compared to
KN1, right: ΔM1M2 mice compared to KN1. C: Survival curves of 4D5 treated animals distributed by different mouse strains. Left: WT vs. ΔM1M2, middle: WT vs.
KN1, right: ΔM1M2 vs. KN1. Full lines: WT mice, dashed lines: KN1 mice, dotted lines: ΔM1M2 mice; ns … not significant, * … p < 0.05, ** … p < 0.01.
J. Singer et al. World Allergy Organization Journal 12 (2019) 100044further research studies into this field. Second, in the absence of a re-
combinant mouse anti HER-2 IgE antibody of the same specificity as 4D5,
a side-by-side comparison of IgE versus IgG istotypes could not be done to
compare the potential of IgG versus IgE-based immunotherapies.
Furthermore, adoptive transfer experiments of sera from high-IgE to low-
IgE mice could have further elucidated the role of IgE in immuno-
surveillance and defense of cancer. Finally, the mouse immune system
does not fully mirror the human setting and generally such experiments
would only constitute an impression of the human immune system
setting. For instance, murine dendritic cells do not express FcεRI, which
hinders conclusions on the IgE-mediated antigen presentation capacity of
the used transgenic mouse models.8
Conclusion
This study highlights: i) that anticancer vaccines targeting HER-2
provide a significant survival benefit and delay disease progression in
an immunocompetent syngeneic mouse model of cancer, ii) that vacci-
nation was superior to passive antibody therapy with the anti-HER-2
IgG1 antibody 4D5 in WT and low-IgE expressing mice, and iii) the
protective effects of elevated natural IgE levels after tumor challenge
compared with normal- or low-IgE expressing mice who did not undergo
any intervention. IgE therefore has a natural surveillance function against
malignant cells, together with its cytotoxic cellular effector arm. Epide-
miologic studies indicate that atopics with elevated IgE may benefit from
its innate immune surveillance and functions. We propose that in non-
atopic patients, the benefits of IgE can be exploited and improved by
targeting recombinant IgE antibodies to cancer antigens. While low-IgE
conditions pose a higher risk for progressive cancer, these individuals
may benefit from anticancer immunotherapies. Based on our study and in
line with the AllergoOncology concept, we propose that IgE should be
reinvented to target cancer antigens.7,8,13,35,487Conflict of interest
Sophia N. Karagiannis is scientific founder of IGEM Therapeutics, a
UK-based Immuno-Oncology company. The other authors declare no
conflict of interest.
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